Literature DB >> 31483688

Epidermal Growth Factor Receptor Blockade in Head and Neck Cancer: What Remains?

Michael J Jelinek1, Everett E Vokes2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31483688     DOI： 10.1200/JCO.19.01981

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

1.  A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.

Authors:  Sara E Kochanny; Francis P Worden; Douglas R Adkins; Dean W Lim; Julie E Bauman; Stephanie A Wagner; Ryan J Brisson; Theodore G Karrison; Walter M Stadler; Everett E Vokes; Tanguy Y Seiwert
Journal:  Cancer       Date:  2020-02-19       Impact factor: 6.860

2.  An Exploratory Study of Neoadjuvant Cetuximab Followed by Cetuximab and Chemoradiotherapy in Women With Newly Diagnosed Locally Advanced Cervical Cancer.

Authors:  Paula M Fracasso; Linda R Duska; Premal H Thaker; Feng Gao; Imran Zoberi; Farrokh Dehdashti; Barry A Siegel; Livnat Uliel; Christine O Menias; Patrice K Rehm; Sherry A Goodner; Allison N Creekmore; Heather L Lothamer; Janet S Rader
Journal:  Am J Clin Oncol       Date:  2022-06-07       Impact factor: 2.787

Review 3.  De-intensification for HPV positive oropharyngeal cancer: and yet it moves!: 2019 in review.

Authors:  Pierluigi Bonomo; Lorenzo Livi
Journal:  Clin Transl Radiat Oncol       Date:  2020-03-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.